NCT03884439Completed
Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)
Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" General Investigation (Crohn's Disease or Ulcerative Colitis)
Source: ClinicalTrials.gov · Last updated 21 Mar 2025
Brief summary (registry, in English)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against Crohn's disease or ulcerative colitis under actual status of use.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 428 (actual)
- First submitted
- 4 Mar 2019
- Start date
- 18 Mar 2019
- Primary completion date
- 2 Feb 2024
- Lead sponsor
- Pfizer
- Diseases
- Crohn's disease, Ulcerative colitis
- NCT number
- NCT03884439
What you commit to
- Study type: Observational
- Participants enrolled: 428
- From 18 Mar 2019 to the primary completion date, 2 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Patients with Crohn's disease or ulcerative colitis who started treatment with this drug
- Patients who received this drug for the first time at the medical institution after the day of launch of this drug.
Age in the registry: 0 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Local Country Office Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.